The Drug Delivery and Targeting group from the CIBBIM-Nanomedicine at VHIR, led by Dr. Simó Schwartz Jr., participates in a new European project, which aims the innovation and improvement in the treatment for Fabry disease, a rare condition X-linked which affects 1 in 7.000 people...
Prof. Jan Skov Pedersen, Department of Chemistry and iNANO, is part of the new Horizon 2020 Framework Programme project “Smart-4-Fabry” (Smart multifunctional GLA-nanoformulation). The project is funded under the action 'H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies'. The project started on...
Los trastornos de almacenamiento lisosomal (LSD) son un grupo de enfermedades raras que en la actualidad carecen de una cura definitiva. En el caso de la enfermedad de Fabry, existe una deficiencia en α-galactosidasa A (GLA). Como resultado de la inexistencia de la enzima se...
Nanomol Technologies is part of the new Horizon 2020 Framework Programme project “Smart-4-Fabry” (Smart multifunctional GLA-nanoformulation for Fabry disease) The project has started on January 1st, 2017, and will run for 4 years with 10 partners and a budget of 5,800,000 €. The research of Smart-4-Fabry project concerns development of drug...
Kick-off Meeting of the Smart-4-Fabry Project will be held in Barcelona from the 16th to the 19th January 2017....